Aha: Mixed Results With Dapagliflozin In T2d Patients | Latest News RSS feed

Aha: Mixed Results With Dapagliflozin In T2d Patients - Latest News


AHA: Mixed Results with Dapagliflozin in T2D Patients

CHICAGO -- Dapagliflozin (Farxiga) did not led to a difference in the rate of major adverse cardiovascular events (MACE) in diabetic patients with or at risk for atherosclerotic cardiovascular disease ... read more

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor ... Clinical trial results ... read more

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor ... Clinical trial results ... read more

Looking for another news?


Significantly reduced cardiovascular complications in patient population with type 2 diabetes: AstraZeneca

AstraZeneca’s commented “DECLARE confirmed the well-established safety profile of dapagliflozin in this landmark trial of over 17,000 patients for 4.2 years, in a population representative of the ... read more


Forxiga significantly reduced hospitalisation for...

MISSISSAUGA, ON, Nov. 10, 2018 /CNW/ - AstraZeneca today announced positive full results from ... for Forxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the ... read more

The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase ... of the largest trials in broad patient populations with Farxiga (dapagliflozin) ... read more

Antisense Lp(a) Agent; Overdose Drug with AEDs; Mixed CV Results for T2D Drug

The SGLT2 inhibitor dapagliflozin (Farxiga) failed to reduce major cardiovascular ... Sensitive Troponin-I assay as a diagnostic test to predict heart disease even in patients without cardiac symptoms ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us